Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
I

Inuvo Inc
F:CD5N

Watchlist Manager
Inuvo Inc
F:CD5N
Watchlist
Price: 4 EUR -9.5% Market Closed
Market Cap: €560.6m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

CD5N Price Targets Summary
Inuvo Inc

Wall Street analysts forecast CD5N stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CD5N is 20.35 EUR with a low forecast of 12.24 EUR and a high forecast of 25.45 EUR.

CD5N Lowest Forecast
Wall Street Target
12.24 EUR
206% Upside
CD5N Average Forecast
Wall Street Target
20.35 EUR
409% Upside
CD5N Highest Forecast
Wall Street Target
25.45 EUR
536% Upside
Lowest
Price Target
12.24 EUR
206% Upside
Average
Price Target
20.35 EUR
409% Upside
Highest
Price Target
25.45 EUR
536% Upside
Inuvo Inc Competitors:
Price Targets
DMAS
Puradelta Lestari Tbk PT
18% Upside
BDSX
Biodesix Inc
146% Upside
BIRD
Allbirds Inc
348% Upside
DMAS
Puradelta Lestari Tbk PT
18% Upside
BDSX
Biodesix Inc
146% Upside
BIRD
Allbirds Inc
348% Upside

Revenue
Forecast

7% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
7% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

For the last 13 years the compound annual growth rate for Inuvo Inc's revenue is 7%. The projected CAGR for the next 3 years is 7%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-75%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-75%
Average Miss

What are analyst estimates?

See Also

Summary
CD5N intrinsic value, competitors valuation, and company profile.
DCF Valuation
CD5N stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CD5N stock valuation using valuation multiples.
Wall Street Estimates
CD5N price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CD5N stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CD5N's stock price target?
Price Target
20.35 EUR

According to Wall Street analysts, the average 1-year price target for CD5N is 20.35 EUR with a low forecast of 12.24 EUR and a high forecast of 25.45 EUR.

What is Inuvo Inc's Revenue forecast?
Projected CAGR
7%

For the last 13 years the compound annual growth rate for Inuvo Inc's revenue is 7%. The projected CAGR for the next 3 years is 7%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.